Mouse models of nonalcoholic steatohepatitis in preclinical drug development - PubMed (original) (raw)

Review

. 2017 Nov;22(11):1707-1718.

doi: 10.1016/j.drudis.2017.06.007. Epub 2017 Jul 4.

Affiliations

• PMID: 28687459
• DOI: 10.1016/j.drudis.2017.06.007

Free article

Review

Mouse models of nonalcoholic steatohepatitis in preclinical drug development

Henrik H Hansen et al. Drug Discov Today. 2017 Nov.

Free article

Abstract

Nonalcoholic fatty liver disease (NAFLD) has become the most common cause of chronic liver disease in the Western world. NAFLD is a complex spectrum of liver diseases ranging from benign hepatic steatosis to its more aggressive necroinflammatory manifestation, nonalcoholic steatohepatitis (NASH). NASH pathogenesis is multifactorial and risk factors are almost identical to those of the metabolic syndrome. This has prompted substantial efforts to identify novel drug therapies for correcting underlying metabolic deficits, and to prevent or alleviate hepatic fibrosis in NASH. Available mouse models of NASH address different aspects of the disease, have varying clinical translatability, and, therefore, also show different utility in drug discovery.

Copyright © 2017 The Authors. Published by Elsevier Ltd.. All rights reserved.

PubMed Disclaimer

Publication types

MeSH terms

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database
  • scite Smart Citations

• Medical

  • MedlinePlus Health Information